NCT04456452 is a Phase 1 clinical trial of Ampion in COVID-19, sponsored by Ampio Pharmaceuticals. Inc..

Who is sponsoring NCT04456452?

NCT04456452 is sponsored by Ampio Pharmaceuticals. Inc..

What drugs are being tested in NCT04456452?

Interventions in NCT04456452: Ampion, Standard of Care.

Is NCT04456452 still recruiting?

NCT04456452 is currently completed. Last updated 13 January 2021.

Last reviewed 2021-01-13 · How we verify

NCT04456452

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation

Completed Phase 1 Last updated 13 January 2021

What this trial tests

Phase 1 trial testing Ampion in COVID-19 in 10 participants. Completed in 30 November 2020.

Timeline

27 July 2020

Primary endpoint
8 September 2020

30 November 2020

Quick facts

Lead sponsor	Ampio Pharmaceuticals. Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	10
Start date	27 July 2020
Primary completion	8 September 2020
Estimated completion	30 November 2020
Sites	1 location across United States

Drugs / interventions tested

Ampion — full drug profile →
Standard of Care

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Ampio Pharmaceuticals. Inc. — full company profile →

Who can join

Adults 18 to 89, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1 randomized study to evaluate the safety, tolerability and efficacy of IV Ampion in improving the clinical course and outcomes of patients hospitalized with COVID-19 infection who require supplemental oxygen.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895
Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2.
Mousavi Maleki MS, Rostamian M, Madanchi H. · · 2021 · cited 40× · PMID 33844613 · DOI 10.1080/14787210.2021.1912593

Verify or expand the search:

Other trials of Ampion

Trials testing the same drug.

NCT04880161 — A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID) · Phase 1 · completed
NCT04839965 — Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen · Phase 2 · terminated
NCT04868890 — A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19 · Phase 2 · terminated
NCT04606784 — Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress · Phase 1 · completed
NCT03988023 — Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee. · Phase 3 · terminated

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Ampio Pharmaceuticals. Inc. trials

Trials by the same sponsor.

NCT04880161 — A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID) · Phase 1 · completed
NCT04839965 — Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen · Phase 2 · terminated
NCT04868890 — A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19 · Phase 2 · terminated
NCT04606784 — Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress · Phase 1 · completed
NCT03988023 — Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee. · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04456452 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ampio Pharmaceuticals. Inc.
Last refreshed: 13 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04456452.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing